Loading...
Market
Will Phathom Pharmaceuticals announce a new drug approval by June 30, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Phathom Pharmaceuticals or FDA announcements
Story
Phathom Pharmaceuticals Receives FDA Approval for VOQUEZNA for GERD Heartburn Relief in Adults
Jul 18, 2024, 12:04 PM
Phathom Pharmaceuticals has received FDA approval for its drug VOQUEZNA (vonoprazan) tablets. The medication is intended for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. This approval, announced on July 17 and July 18, marks a significant milestone for Phathom Pharmaceuticals, which has a short interest of over 40%. VOQUEZNA is a potassium-competitive acid blocker (PCAB), expanding its approval to cover more GERD patients.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Another cancer therapy • 25%
A non-cancer therapy • 25%
No new approvals • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
